Safety and efficacy in clinical studies on pemetrexed and gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer

Objective To compare the clinical efficacy and adverse reactions of the pemetrexed and gemcitabine compared with carboplatin in first-line treatment of advanced non-small cell lung cancer,and explore the feasibility of the program. Methods 37 cases of histologically confirmed advanced non-small cell lung cancer patients were selected from the new hospital(from May 2011 to November 2012),they were randomly divided into two groups according to the treatment plan: group A included 19 cases,they used pemetrexed and carboplatin; group B included 18 cases, they used gemcitabine and carboplatin. The efficacy and adverse reactions of chemotherapy were evaluated after three weeks. Results(1)There were no significant difference in ORR and DCR between group A and group B(P 0.05).(2)PFS of group A was higher than group B, the difference was significant(P 0.05).There were no significant difference in 1-year overall survival between group A and group B(P 0.05).(3)The side effects rate of group A was lower than group B,the difference was significant(P 0.05). Conclusion The efficacy of pemetrexed and carboplatin in first-line treatment of advanced non-small cell lung cancer and efficacy of gemcitabine and carboplatin are similar,and well tolerated,can significantly improve patient's compliance and can be extended to the clinic.